Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing
drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned
drug discovery subsidiary, ReceptoPharm, Inc., has successfully completed the
Phase IIb/IIIa clinical trial of its leading drug candidate for neurological and
autoimmune disorders, RPI-78M, as a treatment for Adrenomyeloneuropathy
"Completing this clinical trial is an important achievement for
both Nutra Pharma and ReceptoPharm," commented Paul Reid, CEO of ReceptoPharm.
"Our next step is to compile, analyze and present the results from this trial to
the medical community," he concluded.
Adrenomyeloneuropathy (AMN) is a
rare inherited metabolic disorder that affects approximately 30,000 people
worldwide. The disorder is characterized by the loss of the fatty covering
(myelin sheath) on nerve fibers within the brain (cerebral demyelination) and
the progressive degeneration of the adrenal gland (adrenal atrophy).
Neurological disability in AMN is slowly progressive over several decades.
AMN interests the wider neurologic community because of its similarities
to Multiple Sclerosis (MS). There is currently no approved treatment for AMN.
Additionally, the disease's rarity designates it as an orphan drug candidate
both in Europe and in the U.S. The Company has applied for Orphan drug status in
the U.S. and intends doing so for the EU.
"Once the data from this trial
has been presented, we will continue to expand ReceptoPharm's clinical
development program," explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma
Corporation. "Currently, we are planning several additional clinical trials,
including those for the treatment of Multiple Sclerosis using RPI-78M and the
treatment of Rabies and HIV using RPI-MN," he added. ReceptoPharm expects to
present the clinical findings from the study by the end of
September.About Nutra Pharma Corp.
Nutra Pharma Corp. is
a biopharmaceutical company specializing in the acquisition, licensing and
commercialization of pharmaceutical products and technologies for the management
of neurological disorders, cancer, autoimmune and infectious diseases. Nutra
Pharma Corp. through its subsidiaries carries out basic drug discovery research
and clinical development and also seeks strategic licensing partnerships to
reduce the risks associated with the drug development process. The Company's
subsidiary, ReceptoPharm, Inc., is developing these technologies for the
production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's
subsidiary, Designer Diagnostics, is engaged in the research and development of
diagnostic test kits designed to be used for the rapid identification of
infectious diseases such as Tuberculosis (TB) and Mycobacterium
avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire
intellectual property and companies in the biotechnology arena. SEC
This press release contains forward-looking statements.
The words or phrases "would be," "will allow," "intends to," "will likely
result," "are expected to," "will continue," "is anticipated," "estimate,"
"project," or similar expressions are intended to identify "forward-looking
statements." Actual results could differ materially from those projected in
Nutra Pharma's ("the Company") business plan. The Company's business is subject
to various risks, which are discussed in the Company's filings with the
Securities and Exchange Commission ("SEC"). The completion of ReceptoPharm's
Phase IIb/IIIa clinical trial for treating Adrenomyeloneuropathy should not be
construed as an indication in any way whatsoever of the value of the Company or
its common stock. The Company's filings may be accessed at the SEC's Edgar
system at http://www.sec.gov
. Statements made herein are as of the date
of this press release and should not be relied upon as of any subsequent date.
The Company cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we specifically
disclaim any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances after the date
of such statement.http://www.NutraPharma.comhttp://www.ReceptoPharm.com